Revolution Medicines brought new updated data for daraxonrasib into the first-line pancreatic cancer discussion at AACR, extending the company’s already strong momentum around RAS(ON) inhibition. The company reported additional first-line phase I/II findings in metastatic PDAC, including monotherapy and combination cohorts. The AACR updates followed Revolution’s earlier phase III signal in previously treated metastatic PDAC, which had driven major market attention after the company described a median overall survival improvement versus chemotherapy. Analysts and clinicians are now focused on whether the first-line results reinforce daraxonrasib’s durability and broad activity across RAS-altered and RAS wild-type tumors. For biotech pipeline planning, the narrative is clear: RAS-directed programs are moving from late-line proof toward earlier-stage positioning, with combination strategies likely to become the next competitive battleground.